Olatec Therapeutics
Sophia Skouras has extensive experience in investor relations and communications, currently serving as Investor Relations, Public Relations & Communications at Olatec Therapeutics LLC since October 2014. Prior to this role, Sophia held the position of Chief Administrator, Investor Relations & Operations at Olatec Therapeutics LLC from August 2012 to 2014 and interned as an Assistant to the Director of Communications at Olatec Industries LLC in May 2011. Educationally, Sophia holds a Bachelor of Arts in Communication from Wake Forest University and has pursued further studies at Wake Forest Schools of Business, The Taft School, and Greenwich Academy.
This person is not in any teams
Olatec Therapeutics
Olatec is a privately held biopharmaceutical company developing a platform of safe, oral NLRP3 antagonist therapeutics, to treat and prevent a broad spectrum of acute and chronic inflammatory diseases that are known to be mediated by Interleukin-1 (IL-1), including: arthritis, heart failure, asthma, Alzheimer’s disease, multiple sclerosis, type-2 diabetes, melanoma and breast cancers, among others.